Valor nutritivo do bagaço de cana-de-açúcar amonizado com quatro doses de uréia

O objetivo deste trabalho foi avaliar a composição químico-bromatológica e a digestibilidade in vitro do bagaço de cana-de-açúcar, submetido à amonização com uréia. Os tratamentos constaram de quatro doses de uréia, adicionadas ao bagaço de cana-de-açúcar, e adição de 1,2% de soja como fonte de urease. O delineamento experimental utilizado foi o inteiramente casualizado. O bagaço foi armazenado em silos de PVC com capacidade para 5,3 L, que foram abertos depois de 110 dias de amonização. Com a adição das doses de uréia ao bagaço, houve aumento linear nos teores de proteína bruta. Os teores de fibra em detergente neutro, fibra em detergente ácido, hemicelulose, celulose, lignina e carboidratos totais diminuíram, enquanto os teores de nitrogênio insolúvel em detergente ácido, nitrogênio insolúvel em detergente neutro, carboidratos não fibrosos, nitrogênio amoniacal e pH aumentaram, significativamente, com a adição de uréia. Nas doses avaliadas, a uréia adicionada ao bagaço promove aumento no conteúdo dos compostos nitrogenados, diminuição dos componentes fibrosos e aumenta a digestibilidade in vitro da matéria seca. Estimada pela equação de regressão, a adição de 2,62% de uréia ao bagaço de cana fornece o teor mínimo de proteína bruta para o bom funcionamento do rúmen.

Allergologie: 2. Mastocytose systémique--nouvelles stratégies thérapeutiques [Systemic mastocytosis--new therapeutic strategies].

Systemic mastocytosis is characterized by an excessive proliferation of mast cells and their accumulation in different organs. Avoidance of trigger factors leading to anaphylaxis is a general measure valid for all forms of mastocytosis. A premedication is necessary in case of surgery, anesthesia or administration of radiocontrast agents. Symptomatic treatment comprises antihistamines, anti-leukotrienes, proton pump inhibitors and topical corticosteroids. Indolent mastocytosis with refractory symptoms, the rare cases of aggressive mastocytosis with organ dysfunction and the even rarer mast cell leukemia require cytoreductive therapy. First-line agents are interferon alpha 2b and imatinib, a tyrosine kinase inhibitor. To date there is no curative treatment.

Hormonal control of spermatogenesis in men: therapeutic aspects in hypogonadotropic hypogonadism.

During the first two trimesters of intrauterine life, fetal sex steroid production is driven by maternal human chorionic gonadotropin (hCG). The HPG axis is activated around the third trimester and remains active for the first 6-months of neonatal life. This so-called mini-puberty is a developmental window that has profound effects on future potential for fertility. In early puberty, GnRH secretion is reactivated first at night and then night and day. Pulsatile GnRH stimulates both LH and FSH, which induce maturation of the seminiferous tubules and Leydig cells. Congenital hypogonadotropic hypogonadism (CHH) results from GnRH deficiency. Men with CHH lack the mini-pubertal and pubertal periods of Sertoli Cell proliferation and thus present with prepubertal testes (<4mL) and low inhibin serum levels --reflecting diminished SC numbers. To induce full maturation of the testes, GnRH-deficient patients can be treated with either pulsatile GnRH, hCG or combined gonadotropin therapy (FSH+hCG). Fertility outcomes with each of these regimens are highly variable. Recently, a randomized, open label treatment study (n=13) addressed the question of whether a sequential treatment with FSH alone prior to LH and FSH (via GnRH pump) could enhance fertility outcomes. All men receiving the sequential treatment developed sperm in the ejaculate, whereas 2/6 men in the other group remained azoospermic. A large, multicenter clinical trial is needed to definitively prove the optimal treatment approach for severe CHH.

CD4+CD25+Foxp3+ regulatory T cells: from basic research to potential therapeutic use.

Regulatory T cells control immune responses to self- and foreign-antigens and play a major role in maintaining the balance between immunity and tolerance. This article reviews recent key developments in the field of CD4+CD25+Foxp3+ regulatory T (TREG) cells. It presents their characteristics and describes their range of activity and mechanisms of action. Some models of diseases triggered by the imbalance between TREG cells and effector pathogenic T cells are described and their potential therapeutic applications in humans are outlined.

Fontes e doses de boro em porta-enxertos de seringueira

Este trabalho teve por objetivo avaliar o efeito da aplicação de boro sobre o incremento do diâmetro do caule no ponto de enxertia, 5 cm acima do coleto, número e diâmetro de raízes laterais e estado nutricional de porta-enxertos para produção de toco enxertado de raiz nua. O delineamento experimental foi o de blocos ao acaso, em esquema fatorial 2x5: duas fontes (ulexita, 10% de B e ácido bórico, 17% de B) e cinco doses de B (0, 2, 4, 8 e 16 kg ha-1) com quatro repetições. Em condições edafoclimáticas locais, curvas de resposta indicam aumentos significativos, no incremento do diâmetro do caule, no ponto de enxertia, nas doses 6,5 e 16 kg ha-1 de B, e no número de raízes laterais, nas doses 13,9 e 16 kg ha-1 de B, com aplicação de ácido bórico e de ulexita, respectivamente. As doses de B não afetaram o número de raízes. O nível crítico de B na folha de mudas de seringueira, alcançado com aplicação de ácido bórico, é de 31,8 mg kg-1. As doses de B apresentam interações significativas com os teores foliares de B, Mn e Zn, enquanto os teores foliares de N, P, K, Ca, Mg, S, Na, Cu e Fe não variaram significativamente em razão das doses de B.

Therapeutic advances in non-small cell lung cancer.

Despite decades of research, therapeutic advances in non-small cell lung cancer (NSCLC) have progressed at a painstaking slow rate with few improvements in standard surgical resection for early stage disease and chemotherapy or radiotherapy for patients with advanced disease. In the past 18 months, however, we seemed to have reached an inflexion point: therapeutic advances that are centred on improvements in the understanding of patient selection, surgery that is undertaken through smaller incisions, identification of candidate mutations accompanied by the development of targeted anticancer treatments with a focus on personalised medicine, improvements to radiotherapy technology, emergence of radiofrequency ablation (RFA), and last but by no means least, the recognition of palliative care as a therapeutic modality in its own right. The contributors to this review are a distinguished international panel of experts who highlight recent advances in each of the major disciplines.

French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs.

The prescription information (summary of product characteristics, SPC) is compiled by the pharmaceutical industry as required by the national regulatory authorities. They vary in their content about the properties of drugs and about the usefulness of therapeutic drug monitoring (TDM) in the blood of patients. Based on a previous study carried out in Germany, the degree of agreement of French SPC for 59 psychotropic drugs with the existing medico-scientific evidence in the area of TDM was examined using a recently developed instrument. A summary score of SPC content (SPCC) related to TDM (SPCC(TDM)) has been calculated and compared with the level of recommendation of TDM of the AGNP-TDM expert group consensus guidelines for TDM in psychiatry [AGNP: Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (Association for neuropsychopharmacology and pharmacopsychiatry)]. Among the antidepressants, antipsychotics, tranquillizers/hypnotic agents and mood stabilizers, the highest SPCC(TDM) scores in the French SPC were reached for imipramine (16), haloperidol (6), clonazepam (8) and lithium (23), respectively. Results were similar to those obtained from the analysis of German SPC, and considerable disagreement was found between the information on TDM in SPC and existing medico-scientific evidence, albeit less in the case of mood stabilizers. Taking into account the recommendations of the AGNP-TDM expert group guidelines, there is a deficit in the French SPC concerning TDM-relevant information. An amelioration of this situation could help to improve the clinical practice of TDM of psychotropic drugs, as the SPC is a widely used tool.

Role of glutathione deficit in the disconnectivity syndrome in schizophrenia: from pathogenetic mechanisms to therapeutic interventions

In the cerebrospinal fluid of 26 drug-naive schizophrenics (DSM-III- R), we observed that the level of glutathione ([GSH]) and of its metabolite γ-Glu-Gln was decreased by 27% and 16% respectively. Using a new in-vivo method based on magnetic resonance spec- troscopy, [GSH] was measured in the medial prefrontal cortex of 18 schizophrenics and found to be 52 % lower than in controls (n = 20). This is consistent with the recently observed decreased mRNA levels in fibroblasts of patients (n=32) of the two GSH synthesizing en- zymes (glutathione synthetase (GSS), and glutamate-cysteine ligase M (GCLM) the modulatory subunit of glutamate-cysteine ligase). Moreover, the level of GCLM expression in fibroblasts correlates neg- atively with the psychopathology (positive, general and some nega- tive symptoms). Thus, the observed difference in gene expression is not only the cause of low brain [GSH], but is also related to the sever- ity of symptoms, suggesting that fibroblasts are adequate surrogate for brain tissue. A hypothesis was proposed, based on a central role of GSH in the pathophysiology of schizophrenia. GSH is an important endogenous redox regulator and neuroactive substance. GSH is pro- tecting cells from damage by reactive oxygen species generated, among others, by the metabolism of dopamine. A GSH deficit-in- duced oxidative stress would lead to lipid peroxidation and micro-le- sions in the surrounding of catecholamine terminals, affecting the synaptic contacts on dendritic spines of cortical neurones, where ex- citatory glutamatergic terminals converge with dopaminergic ones. This would lead to spines degeneration and abnormal nervous con- nections or structural disconnectivity, possibly responsible for posi- tive, perceptive and cognitive symptoms of schizophrenia. In addi- tion, a GSH deficit could also lead to a functional disconnectivity by depressing NMDA neurotransmission, in analogy to phencyclidine effects. Present experimental biochemical, cell biological and behav- ioral data are consistent with the proposed mechanism: decreasing pharmacologically [GSH] in experimental models, with or without blocking DA uptake (GBR12909), induces morphological and behav- ioral changes similar to those observed in patients. Dendritic spines: (a) In neuronal cultures, low [GSH] and DA induce decreased density of neural processes; (b) In developing rats (p5-p16), [GSH] deficit and GBR induce a decrease in normal spines in prefrontal pyramids and in GABA-parvalbumine but not of -calretinine immunoreactivity in anterior cingulate. NMDA-dependant synaptic plasticity: GSH deple- I/13 tion in hippocampal slices impairs long-term potentiation. Develop- ing rats with low [GSH] and GBR have deficit in olfactory integration and in object recognition which appears earlier in males than fe- males, in analogy to the delay of the psychosis onset between man and woman. In summary, a deficit of GSH and/or GSH-related enzymes during early development could constitute a major vulnerability fac- tor in schizophrenia.

Resposta de cultivares de arroz a doses de nitrogênio e do regulador de crescimento cloreto de clormequat

O objetivo deste trabalho foi avaliar os efeitos de doses de nitrogênio (0, 50, 100 e 150 kg ha-1) e do regulador de crescimento cloreto de clormequat (0, 1 e 2 L ha-1), em algumas características agronômicas de cultivares de arroz IAC 201 e IAC 202. O delineamento experimental foi o de blocos ao acaso, com quatro repetições. O N foi aplicado em cobertura, no estádio da diferenciação floral, e o regulador de crescimento foi aplicado parceladamente, aos 20 e 30 dias após a emergência das plântulas de arroz (perfilhamento). Na safra 2001/2002, houve efeito significativo de N para altura de plantas, comprimento da panícula, espiguetas por panícula, massa de 100 grãos e produtividade de grãos. Houve efeito do regulador de crescimento sobre o comprimento da panícula e espiguetas por panícula. A maior produtividade foi a da cultivar IAC 202. Na safra 2002/2003, houve efeito de N para altura de plantas, massa de 100 grãos, fertilidade das espiguetas e produtividade de grãos. O regulador de crescimento não exerceu efeito nas características testadas, e a cultivar IAC 202 foi novamente a mais produtiva.

Rugosidade superficial do solo sob diferentes doses de resíduo de milho submetido à chuva simulada

O objetivo deste trabalho foi avaliar a rugosidade e a tortuosidade da superfície do solo, preparado com diferentes doses de resíduo cultural de milho, e relacioná-las com o volume de chuva simulada. Em um Cambissolo, em La Coruña, Espanha, em agosto de 2005, avaliou-se a rugosidade superficial, no preparo mínimo sob chuva simulada, com as doses de 0, 2, 4, 6 e 8 t ha-1 de resíduo de milho picado e semi-incorporado ao solo. Aplicaram-se oito testes de chuva simulada, com 65 mm h-1 e 60 min cada um. A rugosidade e a tortuosidade, ao acaso, foram menores do que na condição linear e, as desta condição foram menores do que na condição original. A redução da rugosidade e da tortuosidade, em decorrência das chuvas, diminuiu com o aumento da dose de resíduo de milho. A rugosidade superficial foi mais fortemente influenciada quando se eliminou o efeito da declividade do terreno do que quando se eliminaram, simultaneamente, os efeitos da declividade e das marcas de preparo do solo para o seu cálculo.

Combined radioimmunotherapy and chemotherapy of human colon carcinoma grafted in nude mice, advantages and limitations.

In order to determine if 5-fluorouracil (5FU) could potentiate the effect of radioimmunotherapy (RIT), nude mice bearing subcutaneous human colon carcinoma xenografts were treated by 1 or 2 intravenous injection(s) of subtherapeutic doses of 131I labeled F(ab')2 from anti-carcinoembryonic antigen monoclonal antibodies combined with 5 daily intraperitoneal injections of 5FU. Control mice received either 131I F(ab')2 alone, 5FU alone or no treatment. RIT alone induced significant tumor regression, while 5FU alone gave only minimal tumor growth inhibition. The combined treatment group also resulted in long-term tumor regression with tumors remaining significantly smaller than in the RIT alone group. There was however, no significant difference in tumor recurrence time between the groups treated with RIT alone or with RIT + 5FU. Myelotoxicity, the major side effect of RIT, detected by the decrease of peripheral white blood cells (WBC), was shown to be almost identical between the groups receiving only RIT or only 5FU. Surprisingly, there was no cumulative bone marrow toxicity in animals which received 5FU before RIT. Furthermore, in the latter group, the WBC levels after RIT were significantly higher than in the control group receiving only RIT. Taken together, the results demonstrate the higher therapeutic efficiency of RIT as compared to 5FU in this model. They do not show, however, that the combination of the two forms of treatment can induce longer tumor remission. Interestingly, the WBC results suggest that 5FU given before RIT can have a radioprotective effect on bone marrow, possibly by selecting radioresistant bone marrow stem cells.

Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody

S100A4, a member of the S100 calcium-binding protein family secreted by tumor and stromal cells, supports tumorigenesis by stimulating angiogenesis. We demonstrated that S100A4 synergizes with vascular endothelial growth factor (VEGF), via the RAGE receptor, in promoting endothelial cell migration by increasing KDR expression and MMP-9 activity. In vivo overexpression of S100A4 led to a significant increase in tumor growth and vascularization in a human melanoma xenograft M21 model. Conversely, when silencing S100A4 by shRNA technology, a dramatic decrease in tumor development of the pancreatic MiaPACA-2 cell line was observed. Based on these results we developed 5C3, a neutralizing monoclonal antibody against S100A4. This antibody abolished endothelial cell migration, tumor growth and angiogenesis in immunodeficient mouse xenograft models of MiaPACA-2 and M21-S100A4 cells. It is concluded that extracellular S100A4 inhibition is an attractive approach for the treatment of human cancer.